Literature DB >> 2143101

Possible role of acrolein in oxazaphosphorine-induced enhancement of immunological reactivity.

H Blomgren1, M Hallström.   

Abstract

The aim of the present study was to analyze further the immunopotentiating effects of low doses of oxazaphosphorines. We examined 4-hydroperoxycyclophosphamide (4-HC) and mafosfamide, which degrade spontaneously in water without requiring liver enzymes to become active. Both drugs, at concentrations ranging from 0.01 microM to 1 microM, enhanced mitogenic responses of human lymphocytes. Higher concentrations were toxic. Acrolein, which is one of the degradation products of oxazaphosphorines, had similar effects. Immunopotentiation was not monocyte-dependent. Attempts to inactivate released acrolein with human serum reduced toxicity but the immunostimulating property of the drugs remained Similar effects were noted when lymphocytes were exposed to acrolein dissolved in serum. 2-Mercaptoethane-sulfonate (mesna), which is highly reactive with acrolein, reduced the toxicity of solutions of both oxazaphosphorines and acrolein. Immunopotentiation was not clearly demonstrable since mesna itself enhanced the responses. Pretreatment of lymphocytes with 4-HC or mafosfamide did not reduce the capacity of concanavalin A to induce suppressor cells. It is speculated that acrolein may play a role in oxazaphosphorine-induced enhancements of immune responses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143101     DOI: 10.1007/bf01789172

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

Review 2.  Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives.

Authors:  P Hilgard; J Pohl; J Stekar; R Voegeli
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

3.  31P NMR kinetic studies of the intra- and intermolecular alkylation chemistry of phosphoramide mustard and cognate N-phosphorylated derivatives of N,N-bis(2-chloroethyl)amine.

Authors:  T W Engle; G Zon; W Egan
Journal:  J Med Chem       Date:  1982-11       Impact factor: 7.446

Review 4.  Enhancement of the delayed-type hypersensitivity reaction by oxazaphosphorines.

Authors:  J L Turk
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

5.  Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.

Authors:  W Scheef; H O Klein; N Brock; H Burkert; U Günther; H Hoefer-Janker; D Mitrenga; J Schnitker; R Voigtmann
Journal:  Cancer Treat Rep       Date:  1979-03

6.  Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.

Authors:  D Berd; H C Maguire; M J Mastrangelo
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

7.  In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function.

Authors:  J J Smith; E Mihich; H Ozer
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-09

8.  Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.

Authors:  H Blomgren; M Hallström
Journal:  Methods Find Exp Clin Pharmacol       Date:  1989-06

9.  Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice.

Authors:  M Glaser
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

10.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

View more
  1 in total

1.  Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.

Authors:  T H Inge; S K Hoover; J L Frank; T T Kawabata; K P Bethke; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.